Arvinas (ARVN) Other Non-Current Assets (2017 - 2026)
Arvinas (ARVN) recorded quarterly Other Non-Current Assets of $3.5 million in Q1 2026, down 7.89% quarter-over-quarter from $3.8 million in Q4 2025, and down 27.08% on a YoY basis from $4.8 million in Q1 2025.
Arvinas (ARVN) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Arvinas' Other Non-Current Assets history runs 10 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 27.08% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (down 27.08% YoY), while the FY2025 annual figure was $3.8 million, down 53.09% from the prior year.
- Other Non-Current Assets was $3.5 million for Q1 2026 at Arvinas, down from $3.8 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $12.1 million in Q1 2022 to a low of $3.5 million in Q1 2026.
- Historically, Other Non-Current Assets has averaged $8.6 million across 5 years, with a median of $9.9 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets gained 14.85% in 2024, then slumped 62.07% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $10.8 million in 2022, then fell by 3.7% to $10.4 million in 2023, then slipped by 22.12% to $8.1 million in 2024, then slumped by 53.09% to $3.8 million in 2025, then dropped by 7.89% to $3.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $3.5 million (Q1 2026), $3.8 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 3.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.50 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 8.10 Mn |
| Sep 30, 2024 | 9.80 Mn |
| Jun 30, 2024 | 11.60 Mn |
| Mar 31, 2024 | 9.90 Mn |
| Dec 31, 2023 | 10.40 Mn |
| Sep 30, 2023 | 9.60 Mn |
| Jun 30, 2023 | 10.10 Mn |
| Mar 31, 2023 | 10.30 Mn |
| Dec 31, 2022 | 10.80 Mn |
| Sep 30, 2022 | 11.30 Mn |
| Jun 30, 2022 | 11.70 Mn |
| Mar 31, 2022 | 12.10 Mn |
| Dec 31, 2021 | 12.50 Mn |
| Sep 30, 2021 | 12.84 Mn |
| Sep 30, 2020 | 28,777.00 |